Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Participants must be at least 18 years of age at the time of signing the informed consent.~* Participants with T2DM, and treated with diet and exercise.~* Hemoglobin A1c between 7.0% and 10.0% (inclusive) measured by the central laboratory at Screening.~Exclusion criteria:~* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease within 6 months prior to Screening or history of surgery affecting gastric emptying.~* History of pancreatitis (unless pancreatitis was related to gallstone and cholecystectomy has been performed) and pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, and pancreatectomy.~* Personal or family history of Medullary Thyroidian Cancer (MTC) or genetic conditions that predisposes to MTC (eg multiple endocrine neoplasia syndromes).~* Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months of screening) or planned: intravitreal injections or laser or vitrectomy surgery.~* Body weight change of ≥5 kg within the last 3 months prior to Screening.~* Systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>100 mmHg at Randomization.~* End-stage renal disease as defined by estimated glomerular filtration rate (eGFR , by Modification of Diet in Renal Disease \[MDRD\]) of \<15 mL/min/1.73 m2.~* Laboratory findings at the Screening Visit:~* Alanine aminotransferase (ALT ) or aspartate aminotransferase (AST ) \>3 times the upper limit of the normal (ULN ) or total bilirubin \>1.5 times the ULN (except in case of documented Gilbert's syndrome).~* Amylase and/or lipase: \>3 times the ULN laboratory range.~* Calcitonin ≥5.9 pmol/L (20 pg/mL).~* Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to Screening, or planned during study period.~* History of drug or alcohol abuse within 6 months prior to the time of Screening.~* Pregnant (demonstrated by serum pregnancy test at Screening) or breast-feeding women.~* Women of childbearing potential not willing to use highly effective method(s) of birth control during the study period and for at least 5 weeks after the last dose of study intervention.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Efpeglenatide 2mg (Type: EXPERIMENTAL): Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
- Efpeglenatide 4 mg (Type: EXPERIMENTAL): Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
- Efpeglenatide 6 mg (Type: EXPERIMENTAL): Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo (Prefilled syringe) administered once weekly for 56 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).